CD20 is a cell surface protein primarily expressed on the surface of B-cells, a type of white blood cell involved in the immune response. The CD20 molecule plays a critical role in the development, differentiation, and function of B-cells, which are responsible for producing antibodies. It acts as a calcium channel, helping regulate the flow of calcium ions into the cell, a process essential for B-cell activation and immune function. CD20 is not expressed on early B-cell precursors or on plasma cells, which means its expression is limited to specific stages in B-cell maturation.
Because CD20 is highly expressed on the surface of mature B-cells, it has become an important biomarker in diagnosing and treating various B-cell-related diseases, particularly B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). These cancers are characterized by an abnormal proliferation of B-cells, and CD20 serves as a target for therapies designed to eliminate these malignant cells. Rituximab, an anti-CD20 monoclonal antibody, was one of the first therapeutic agents to target this protein, marking a significant advance in cancer treatment.
In addition to its role in cancer treatment, CD20-targeted therapies are also used in autoimmune diseases like rheumatoid arthritis and multiple sclerosis. In these conditions, B-cells contribute to the overactive immune response, and by targeting CD20, therapies can reduce the number of B-cells, thus dampening the immune system’s activity. This strategy helps control inflammation and prevent the immune system from attacking the body's own tissues. CD20-targeted therapies are considered more selective, offering fewer side effects compared to broader immunosuppressive treatments.
Research continues to explore new ways to improve the effectiveness of CD20-targeted therapies. Studies are investigating different combinations of drugs and novel anti-CD20 agents to enhance patient outcomes. These advances hold promise for offering more personalized treatment options for patients suffering from B-cell malignancies and autoimmune diseases, underscoring the importance of CD20 as a pivotal biomarker in modern medicine.
Testing for CD20 is important because it helps identify whether B-cells, specifically in conditions like B-cell Non-Hodgkin Lymphoma (NHL) or chronic lymphocytic leukemia (CLL), express the CD20 protein on their surface. This information is crucial for diagnosis and treatment planning, as CD20-positive B-cells can be targeted by specific therapies, such as monoclonal antibodies like Rituximab. These therapies directly attack the malignant B-cells, improving treatment outcomes. Additionally, CD20 testing helps distinguish different subtypes of lymphomas and guides personalized treatment strategies.
CD20, Abs Count
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.